Tag Archives: Merck

Leadership Changes Announced in Merck Family Board Elections

(IN BRIEF) E. Merck KG, representing the Merck family’s interests in Merck KGaA, has disclosed the results of its regular board elections. Johannes Baillou, with 30 years of board experience at E. Merck KG, has been elected as Chairman of … Read the full press release

Merck Launches Digital Hub in Singapore to Drive Healthcare and Semiconductor Innovation

(IN BRIEF) Merck, a leading science and technology company, has inaugurated the Merck Digital Hub in Singapore, its first digital hub outside of the US and Europe. Supported by the Singapore Economic Development Board (EDB), the hub aims to accelerate … Read the full press release

Merck Expands Biologics Testing Center in China to Support Local Biopharma Innovation

(IN BRIEF) Merck has completed the second phase of its new €29 million Biologics Testing Center in China, adding 1,500 square meters to the facility. This expansion includes the first biosafety laboratories for Merck in the Chinese market, enabling clients … Read the full press release

Merck and Hengrui Unite for Pioneering Cancer Therapies Worldwide

(IN BRIEF) Merck, a prominent science and technology company, has entered into a strategic partnership with Jiangsu Hengrui Pharmaceuticals. This collaboration includes an exclusive global license (excluding China) to develop and commercialize Hengrui’s advanced PARP1 inhibitor, HRS-1167. Additionally, there is … Read the full press release

Merck Outlines Resilience and Growth Strategy, Targets Fiscal 2024 for Sales Uptick

(IN BRIEF) Merck, a leading science and technology company, has announced its expectation to return to organic sales growth in fiscal 2024. This was revealed during the company’s Capital Markets Day. Despite challenging market conditions in its Life Science and … Read the full press release

Merck to Showcase Oncology Portfolio Advancements at ESMO 2023, Highlighting Key Cancer Treatment Breakthroughs

(IN BRIEF) Merck, a leading science and technology company, is set to present 28 abstracts at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting in Madrid. These abstracts will showcase the latest research on Merck’s oncology portfolio, addressing … Read the full press release

Merck’s Evobrutinib Shows Long-Term Efficacy and Improved Quality of Life in Multiple Sclerosis Patients, Revealing Potential RMS Treatment Advancements

(IN BRIEF) Merck has presented new data on evobrutinib, an investigational BTK inhibitor, at the 9th Joint ECTRIMS-ACTRIMS congress. The data from an ongoing Phase II open-label extension study of evobrutinib in patients with relapsing multiple sclerosis (RMS) show sustained … Read the full press release

Merck’s MAVENCLAD Shows Sustained Reduction in Neuronal Injury for Multiple Sclerosis Patients

(IN BRIEF) Merck, a prominent science and technology company, has revealed new findings from the MAVENCLAD® (cladribine tablets) MAGNIFY-MS study at the 9th Joint ECTRIMS-ACTRIMS meeting in Milan. The study demonstrated that patients with relapsing multiple sclerosis (RMS) experienced a … Read the full press release

Merck Partners with UN on Vital Training Course for Family Carers During European Carers Day

(IN BRIEF) Merck, a prominent science and technology company, has entered into a collaboration with the United Nations’ Global Initiative on Ageing (GIA) to offer a training course aimed at equipping family carers with essential skills. The course comprises five … Read the full press release

Merck Forms AI-Driven Drug Discovery Collaborations with BenevolentAI and Exscientia

(IN BRIEF) Merck, a prominent science and technology company, has announced strategic drug discovery collaborations with AI technology firms BenevolentAI and Exscientia. These partnerships aim to leverage AI-driven design and discovery capabilities to advance research efforts in key therapeutic areas, … Read the full press release

Merck to exhibit innovative pigment development for automotive coatings at European Coatings Show 2023

(IN BRIEF) Merck will showcase innovative ideas and new products for the paint and coatings industry at the European Coatings Show 2023 in Germany. One of the highlights will be the latest pigment development from the company that enables Surface … Read the full press release

Merck and Intel fund academic research program in Europe to drive sustainable semiconductor manufacturing with AI and machine learning

(IN BRIEF) Merck and Intel have signed a memorandum of understanding to invest in a new academic research program aimed at driving innovation in semiconductor manufacturing processes and technologies using artificial intelligence (AI) and machine learning. The companies will jointly … Read the full press release

Merck hits the 1.5 billionth mark of praziquantel donation in partnership with the World Health Organization for the treatment of neglected tropical disease schistosomiasis in sub-Saharan Africa

(PRESS RELEASE) DARMSTADT, 24-Jan-2022 — /EuropaWire/ — Merck (ETR: MRK), a German multinational leading science and technology company in healthcare, life science, electronics, has announced the company hit a milestone mark in its donation of praziquantel for the treatment of … Read the full press release

New cosmetic ingredient by Merck to help the skin maintain the integrity of the epidermis

New product specifically for the needs of aging skin Essential calcium improves overall skin integrity Halal-certified blend of 100% of plant and mineral origin serves sustainable market trends (PRESS RELEASE) DARMSTADT, 11-Oct-2021 — /EuropaWire/ — Merck (ETR: MRK), a German … Read the full press release

Leadership changes at Merck Electronics: Dorothea Wenzel, Jeff White and Katherine Dei Cas

(PRESS RELEASE) DARMSTADT, 6-Aug-2021 — /EuropaWire/ — The Merck Group (ETR: MRK), a German multinational science and technology company, has announced some leadership changes within its business sector Electronics. Effective September 1, 2021, Jeff White, currently Head of Delivery Systems … Read the full press release

Merck and Inbrain Neuroelectronics to collaborate on next generation of graphene-based bioelectronic therapies for targeted treatment of chronic diseases

Innovation Center project of Merck aims to develop smart neurostimulators for targeted treatment of chronic diseases Second collaboration within the Bioelectronics innovation field of Merck focuses on increasing the selectivity and power efficiency of the device to enable energy intensive … Read the full press release

Merck completes the sale of its Consumer Health business to Procter & Gamble (P&G)

Closing of sale to Procter & Gamble at a cash purchase price of € 3.4 billion completed Successful completion allows Merck to further focus on innovation driven businesses in Healthcare, Life Science and Performance Materials Transaction successfully closed within an ambitious timeframe … Read the full press release

Merck to establish an innovation hub in Guangzhou, China

Merck today (12 NOV 2018) signed an agreement with the Guangzhou Development District on innovation development in Southern China. DARMSTADT, Germany / GUANGZHOU, China, 14-Nov-2018 — /EuropaWire/ — Merck, the vibrant science and technology company, today signed an agreement with the … Read the full press release

AstraZeneca and Merck & Co., Inc. announce positive results from the randomised, double-blinded, placebo-controlled, Phase III SOLO-1 trial of Lynparza (olaparib) tablets

Lynparza met primary endpoint of progression-free survival in women with BRCA-mutated advanced ovarian cancer and showed a safety profile consistent with previous trials AstraZeneca and MSD’s Lynparza is the only PARP inhibitor to demonstrate significant activity in the 1st-line maintenance … Read the full press release

Chinese Patent Office issued patent for Merck’s CRISPR technology used in a genomic-integration method for eukaryotic cells

Merck today (23 APR 2018) announced that the Chinese Patent Office has issued a notice granting Merck’s patent application for the company’s CRISPR technology used in a genomic-integration method for eukaryotic cells. Patent in China covers integration of an external … Read the full press release

Merck: EMD Serono, Pfizer Canada receive approval for BAVENCIO™ from Health Canada

First Health Canada approved treatment for rare and aggressive type of skin cancer MISSISSAUGA, ON, 26-Feb-2018 — /EuropaWire/ — Merck, which operates as EMD Serono in the US and Canada, and Pfizer Canada Inc. announced that Health Canada has approved BAVENCIO™ … Read the full press release

Merck appoints Dirk Toepfer as new Chief Information Officer

Toepfer joins from Metro Group, where he served as Head of the IT service company Metro Systems DARMSTADT, 26-Jan-2018 — /EuropaWire/ — Merck, a leading science and technology company, today announced that Dirk Toepfer will join the Group as the new … Read the full press release

Merck: Grant for Growth Innovation (GGI) for 2017 winners announced in Washington, U.S.

Not intended for US/Canada based media The presentation of the grants coincides with the 10th International Meeting of Pediatric Endocrinology The awards program supports advancements in the field of growth and growth disorders DARMSTADT, 19-Sep-2017 — /EuropaWire/ — Merck, a leading … Read the full press release

Merck invests EUR 90 million in four sites in Germany, Switzerland and France

Relocations to drive focus on sites in Darmstadt, Schnelldorf (Germany), Buchs (Switzerland) and Molsheim (France) Sequential implementation until the end of 2022 € 90 million investment. Net impact of approximately minus 200 positions over 5 years DARMSTADT, 13-Jul-2017 — /EuropaWire/ … Read the full press release

World MS Day 2017: Merck launches multiple sclerosis (MS) care partner survey with IACO

Preliminary research indicates most MS carers are between the ages of 18-34, the prime of their lives Largest global MS carer survey with International Alliance of Carer Organizations (IACO) to help identify unmet needs and social impact Darmstadt, Germany, 31-May-2017 … Read the full press release

Merck presented new data on efficacy and safety for investigational Cladribine Tablets at the American Academy of Neurology (AAN)

Subgroup analysis shows >80% reduction in the risk of disability progression with Cladribine Tablets vs placebo DARMSTADT, 02-May-2017 — /EuropaWire/ — Merck, a leading science and technology company, announced the presentation of new analyses of efficacy and safety data for … Read the full press release

Merck: Results of the ADDRESS II Phase IIb multicenter study on atacicept in patients with systemic lupus erythematosus

Data presented at the 2016 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting (Abstract Number: 12L) DARMSTADT, 15-Nov-2016 — /EuropaWire/ — Merck, a leading science and technology company, today announced the results of the ADDRESS II Phase IIb, … Read the full press release

Ovarian Cancer: Merck, Pfizer initiate Phase III study JAVELIN Ovarian 100

First Phase III trial evaluating the addition of an immune checkpoint inhibitor to standard of care in first-line ovarian cancer New investigational regimen will evaluate avelumab in extending progression-free survival in treatment-naïve women Darmstadt, Germany and New York, US, 07-Jul-2016 … Read the full press release

Merck to support the advancement of medical science in the field of fertility through the Grant for Fertility Innovation (GFI) program

Investment reflects company’s commitment to innovation in fertility research Globally, six projects receive funding from this grant cycle Darmstadt, Germany, 07-Jul-2016 — /EuropaWire/ — Merck, a leading science and technology company, today announced it would continue to support the advancement of … Read the full press release

Merck receives global marketing and commercialization rights for Progyny’s Early Embryo Viability Assessment (Eeva®) software

Merck obtains global marketing and commercialization rights for the innovative Progyny Eeva® software offering, aiming to provide customers worldwide with innovative fertility technologies solutions This new agreement builds on the successful relationship between both leaders in fertility technologies, first established … Read the full press release

Merck CEO and Chairman of the Executive Board honoured with Weizmann Award in the Sciences and Humanities

Darmstadt, Germany, and Rehovot, Israel, 18-Feb-2016 — /EuropaWire/ — Merck, a leading science and technology company, announced that the Weizmann Institute, Rehovot, Israel, conferred the renowned Weizmann Award in the Sciences and Humanities on Karl-Ludwig Kley, CEO and Chairman of the … Read the full press release

Merck extends partnership with Weizmann Institute of Science on research collaboration

Darmstadt, Germany, and Rehovot, Israel, 18-Feb-2016 — /EuropaWire/ — Merck, a leading science and technology company, today extended the partnership with Weizmann Institute of Science, Rehovot, Israel, of by signing a new framework agreement, building on a successful innovation partnership of … Read the full press release

Merck’s acquisition of Sigma-Aldrich approved by the European Commission under EU Merger Regulation

BRUSSELS, 18-6-2015 — /EuropaWire/ — The European Commission has approved the proposed acquisition of Sigma-Aldrich by Merck under the EU Merger Regulation. Both companies are active world-wide in the life science sector. The decision is conditional on the divestment of … Read the full press release

Merck clarifies that it will keep its consumer health business

• Darmstadt-based company holds global rights to the name Merck with exception of the U.S. and Canada Darmstadt, Germany,  7-5-2014 — /EuropaWire/ — Merck, the supplier of top-quality high-tech products in the pharmaceuticals and chemicals sectors, today clarified that it will … Read the full press release

Merck announced the enrollment of first patient into new Phase III study in the area of fertility

• The ESPART* Phase III clinical study focuses on patients that respond poorly to attempts at ovarian stimulation • Study aims to recruit 946 patients across 17 European countries Darmstadt, Germany, 28-3-2014 — /EuropaWire/ — Merck, the global pharmaceutical and chemical company, … Read the full press release